I believe that it's clear that the company has expected things to happen in less time than it's taken, that's especially true of time to publication of the Journal, but I believe it's been true of many things, like the time to gain approval of the SAP.
I think that DI has tried to base what he's saying on the company's expectations, but he's never established firm deadlines that failed to be met. In other biotech's I've often seen the same sort of slippage between their estimates of when things will happen and when they actually do. The key is that what they say will happen eventually do happen.
About the only time you get a firm date is when it comes to scheduled presentations, once a company says they'll be presenting at a given conference on a given date, that happens. I would hope that in the next few weeks NWBO essentially takes on sponsorship of Dr. Liau's presentation at SNO, if they do, I believe we'll hear something there that's truly new to us, whether we get a Journal published before it, or not. I'm uncertain how things are done at SNO, but at similar conferences if the company was supporting the presentation, the company could also have a reception in which attendees, and sometimes investors, could speak with the presenter and others from the company and perhaps have a further presentation and Q&A session. In a few cases I've even seen this webcast, in others I've had friends attend and video the presentation. I don't know if that's permitted at SNO, I know people who've attended such receptions at ASCO.
I believe we'll see the Abstract for SNO on November 11th, depending on what's said in the Abstract it may be clear that new material is being discussed there, but perhaps not. Let's see what the Abstract says. We're now just over 3 weeks from the Abstracts being revealed and less than 5 weeks from the presentation. I believe the odds could be good for the Journal to come out between the time the Abstract is revealed, and the presentation, but it's by no means certain to any of us, but it could be known by Dr. Liau, and perhaps even the company. As I understand it, when a publisher knows that such a presentation has been scheduled, the publication will be scheduled for release in this time period.
I suppose a question in our minds should be, will the stock price run up prior to either the Abstract release, or the actual presentation at SNO as it did for NYAS until AdamF went to work and alleged that Dr. Liau was bailing out on an unsuccessful trial by lying about having Covid. In the case of NYAS, no Abstract was tied to the presentation, however the company was clearly looking forward to the presentation and it was known that nearly all the key personnel was in attendance. Let's see if the company is supporting SNO in a similar manner. If the company is truly supporting the presentation I would expect that we'd get a PR by shortly after the Abstract was available at the latest.
Gary
Market Data 
Markets 
AI
